<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054842</url>
  </required_header>
  <id_info>
    <org_study_id>HR-SP2086-304</org_study_id>
    <nct_id>NCT05054842</nct_id>
  </id_info>
  <brief_title>Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes</brief_title>
  <official_title>Efficacy and Safety of Retagliptin Phosphate in Combination With Metformin in Type 2 Diabetic Subjects With Poor Metformin Glycemic Control: a Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retagliptin phosphate tablet is a DPP IV inhibitor durg，study number is HR-SP2086-304. The&#xD;
      primary purpose of the study is to evaluate the efficacy of the combination of Retagliptin&#xD;
      phosphate and metformin compared with placebo and metformin in type 2 diabetes subjects with&#xD;
      poor glycemic control treated with metformin for 16 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">September 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SP2086 VS. Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in HbA1c relative to baseline</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with HbA1c&lt;6.5% and HbA1c&lt; 7% after 16 weeks of treatment</measure>
    <time_frame>up to 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting plasma glucose relative to baseline</measure>
    <time_frame>up to 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 2h postprandial blood glucose relative to baseline</measure>
    <time_frame>up to 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight relative to baseline</measure>
    <time_frame>up to 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects in each group who received remedial treatment</measure>
    <time_frame>up to 16 weeks of treatment]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events of SP2086</measure>
    <time_frame>From Day 1 to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of Hypoglycemic event of SP2086</measure>
    <time_frame>From Day 1 to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the concentrations of SP2086 in Type 2 diabetes</measure>
    <time_frame>up to 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the concentration of the main metabolite of SP2086 in Type 2 diabetes</measure>
    <time_frame>up to 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retagliptin phosphate tablets、metformin sustained-release tablets</intervention_name>
    <description>Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication</description>
    <arm_group_label>treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retagliptin phosphate placebo tablets、metformin sustained-release tablets</intervention_name>
    <description>Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication</description>
    <arm_group_label>treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily signed the informed consent, understood the procedures and methods of the&#xD;
             study, and was willing to complete the study strictly in accordance with the clinical&#xD;
             trial protocol;&#xD;
&#xD;
          2. The screening age should be 18-75 years old (including both ends), male or female;&#xD;
&#xD;
          3. Diagnosed with type 2 diabetes, 7.5%≤HbA1c≤11%;&#xD;
&#xD;
          4. At least 8 weeks prior to screening, in addition to regular diet control and exercise,&#xD;
             a steady dose of metformin ≥1500mg/d;&#xD;
&#xD;
          5. Fasting glucose ≤13.3mmol/L; 6、19.0 &lt; BMI 35.0 kg/m2 or less.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. General situation:&#xD;
&#xD;
               -  1) Known or suspected allergy to DPP4i drugs or investigational drug excipients;&#xD;
&#xD;
               -  2) Pregnant or lactating women, fertile men or women were unwilling to use&#xD;
                  contraception during the study period;&#xD;
&#xD;
          2. History or evidence of any of the following diseases at the time of screening:&#xD;
&#xD;
               -  1) Type 1 diabetes, single-gene mutation diabetes, diabetes due to pancreatic&#xD;
                  damage, or other secondary diabetes (e.g., diabetes due to Cushing's syndrome or&#xD;
                  acromegaly);&#xD;
&#xD;
               -  2) Acute metabolic complications (such as ketoacidosis, lactic acidosis or&#xD;
                  hypertonic coma) occurred within 6 months prior to screening; Or have serious&#xD;
                  chronic complications of diabetes in the past (such as severe macrovascular or&#xD;
                  microvascular complications as judged by the investigator) and the investigator&#xD;
                  considers that they are not suitable to participate in this study;&#xD;
&#xD;
               -  3) There is a history of severe hypoglycemia (such as drowsiness, disturbance of&#xD;
                  consciousness, delirium, or even coma caused by hypoglycemia, which requires the&#xD;
                  assistance of others for treatment), or repeated hypoglycemia (≥3 symptomatic&#xD;
                  hypoglycemia within a week, or blood glucose &lt;3.0 mmol/L detected at least 3&#xD;
                  times within a week);&#xD;
&#xD;
               -  4) Patients with poorly controlled hypertension at screening were defined as&#xD;
                  systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP)&#xD;
                  ≥100 mmHg;&#xD;
&#xD;
               -  5) Had myocardial infarction, unstable angina, stroke (except lacunar infarction&#xD;
                  without attack symptoms) or transient ischemic attack, or had undergone coronary&#xD;
                  angioplasty, percutaneous coronary stent implantation or coronary artery bypass&#xD;
                  grafting within 6 months prior to screening; Or had congestive heart failure&#xD;
                  (NYHA grades III and IV), unstable or acute congestive heart failure, or&#xD;
                  persistent arrhythmias that the investigator determined significantly affected&#xD;
                  the subjects' safety within the 6 months prior to screening;&#xD;
&#xD;
               -  6) History of acute and chronic pancreatitis, or risk factors that may lead to&#xD;
                  pancreatitis, such as history of symptomatic gallbladder, history of pancreatic&#xD;
                  injury, etc. (except cholecystectomy);&#xD;
&#xD;
               -  7) A history of malignant tumor within 5 years prior to screening, excluding&#xD;
                  treated local basal cell carcinoma of the skin;&#xD;
&#xD;
               -  8) have obvious diseases of the blood system (such as aplastic anemia,&#xD;
                  myelodysplastic syndrome, hemolytic anemia) or any diseases causing hemolysis or&#xD;
                  red blood cell instability (such as malaria);&#xD;
&#xD;
               -  9) Clinically significant gastric emptying abnormalities (e.g., gastric outlet&#xD;
                  obstruction), severe chronic gastrointestinal diseases (e.g., active ulcers&#xD;
                  within 6 months prior to screening);&#xD;
&#xD;
               -  10) There is a history of drug or alcohol abuse within 3 months prior to&#xD;
                  screening, which may affect the subject's compliance to participate in the test&#xD;
                  according to the investigator's judgment;&#xD;
&#xD;
          3. Received any of the following pharmacological or non-pharmacological treatments or&#xD;
             procedures prior to screening:&#xD;
&#xD;
               -  1) Any hypoglycemic drug treatment other than metformin within 2 months prior to&#xD;
                  screening, including Chinese herbal therapy for hypoglycemic purposes (except&#xD;
                  cumulative use ≤7 days);&#xD;
&#xD;
               -  2) received systemic steroid hormone therapy (including intravenous and oral&#xD;
                  administration) and intraarticular administration for more than 7 days within 2&#xD;
                  months prior to screening;&#xD;
&#xD;
               -  3) Bariatric surgery or procedures (e.g. gastric banding surgery) within 12&#xD;
                  months prior to screening, or use of weight-loss medications within 3 months&#xD;
                  prior to screening, or weight fluctuation ≥10% within 3 months prior to&#xD;
                  screening;&#xD;
&#xD;
               -  4) Have received other gastrointestinal surgery that may lead to malabsorption&#xD;
                  before screening, or long-term use of drugs that directly affect gastrointestinal&#xD;
                  motility;&#xD;
&#xD;
               -  5) Have received blood transfusion, blood donation or blood loss ≥400 mL within 3&#xD;
                  months before screening;&#xD;
&#xD;
               -  6) Participated in clinical trials of any drug or medical device within 3 months&#xD;
                  prior to screening (subject to entering into randomised procedures);&#xD;
&#xD;
          4. Any of the laboratory test indicators during screening meet the following standards&#xD;
             (those who meet the criteria can be retested once within one week if there is a clear&#xD;
             reason for retesting) :&#xD;
&#xD;
               -  1) Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)&#xD;
                  ≥3.0×ULN and/or total bilirubin ≥2.0×ULN;&#xD;
&#xD;
               -  2) patients with renal function injury were defined as eGFR &lt;60ml/min/1.73 m2&#xD;
                  (calculated according to the simplified formula of dietary adjustment for renal&#xD;
                  disease (MDRD));&#xD;
&#xD;
               -  3) Thyroid function test: abnormal thyroid stimulating hormone (TSH), serum free&#xD;
                  triiodothyronine (FT3), serum free thyroxine (FT4);&#xD;
&#xD;
               -  4) Fasting triglyceride ≥5.64 mmol/L (500 mg/ dL);&#xD;
&#xD;
               -  5) Blood amylase or lipase exceeded the upper limit of the normal range and was&#xD;
                  clinically significant as judged by researchers&#xD;
&#xD;
          5. Significant abnormal 12-lead electrocardiogram (ECG) results during screening, which&#xD;
             the investigator considered might affect the safety of the subjects and are not&#xD;
             suitable for this study;&#xD;
&#xD;
          6. Any other conditions (such as affecting the safety or efficacy evaluation of the&#xD;
             subjects) that the investigator deemed inappropriate for the subjects to participate&#xD;
             in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wangwang Zhi</last_name>
    <phone>+86 18036618683</phone>
    <email>Wangwang.zhi@hengrui.com.cn</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

